Eli Lilly & Co. urged doctors to prescribe Zyprexa for elderly patients with dementia, an unapproved use for the antipsychotic, even though the drugmaker had evidence the medicine didn’t work for such patients, according to unsealed internal company documents.
In 1999, four years after Lilly sent study results to the U.S. Food and Drug Administration showing Zyprexa didn’t alleviate dementia symptoms in older patients, it began marketing the drug to those very people, according to documents unsealed in insurer suits against the company for overpayment.
Lilly Sold Drug for Dementia Knowing It Didn’t Help, Files Show
The U.S. is seeing a late summer surge in COVID-19 cases, tracking from the Centers for...
The US’s top public health agency was plunged into chaos on Wednesday after the Trump administration...
Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last...
